OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will ...
Hosted on MSN1mon
TD Cowen Raises Boston Scientific Corporation (BSX) Target to $115, Reaffirms ‘Buy’ Rating Ahead of Q4 ResultsA surgeon examining a patient's brain in an operating room ... On February 3rd, TD Cowen increased Boston Scientific Corporation’s (NYSE:BSX) target price to $115 from $110 and reiterated ...
New research suggests that certain antidepressants may not only help with depression but also improve cognitive functions ...
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and ...
Blood-Brain Barrier Technology ... In conclusion, Alector’s presentation at the TD Cowen Conference underscored its commitment to advancing therapies for neurodegenerative diseases.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback